ArticleNature communications2025

Tifcemalimab as monotherapy or in combination with toripalimab in patients with relapsed/refractory lymphoma: a Phase I trial.

Yuqin Song et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.